SG Americas Securities LLC Acquires 51,792 Shares of BioNTech SE Sponsored ADR $BNTX

SG Americas Securities LLC increased its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 134.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,429 shares of the company’s stock after acquiring an additional 51,792 shares during the period. SG Americas Securities LLC’s holdings in BioNTech were worth $9,628,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Baader Bank Aktiengesellschaft raised its holdings in BioNTech by 6.3% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 151,862 shares of the company’s stock valued at $16,032,000 after buying an additional 9,040 shares during the period. Shell Asset Management Co. boosted its stake in BioNTech by 15.3% during the second quarter. Shell Asset Management Co. now owns 40,610 shares of the company’s stock worth $4,324,000 after buying an additional 5,398 shares during the period. Swedbank AB bought a new position in BioNTech during the first quarter valued at $3,415,000. Millennium Management LLC increased its position in BioNTech by 252.5% during the first quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock valued at $49,625,000 after acquiring an additional 390,360 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its stake in shares of BioNTech by 44.3% in the first quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company’s stock valued at $10,989,000 after acquiring an additional 37,075 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BNTX has been the subject of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. UBS Group upped their target price on BioNTech from $115.00 to $117.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Cowen reiterated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Finally, Morgan Stanley restated an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a report on Monday, November 3rd. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $134.10.

BioNTech Trading Down 0.8%

Shares of NASDAQ BNTX opened at $103.09 on Monday. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $129.27. The firm has a market cap of $24.79 billion, a PE ratio of -64.43 and a beta of 1.54. The business has a fifty day simple moving average of $102.91 and a two-hundred day simple moving average of $104.95. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of $0.75 by ($0.89). The firm had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.21 billion. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business’s quarterly revenue was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.81 EPS. BioNTech has set its FY 2025 guidance at EPS. Analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.